Place of cytology in the diagnosis of systemic mastocytosis: A case report

W. Quiddi; H. Boumaazi; S. Ed-dyb; H. Yahyaoui; M. Aitameur; M. Chakour

doi:10.30574/gscarr.2021.7.2.0096

Authors

W. Quiddi Laboratory of hematology, Military Hospital Avicenne, FMPM- Cadi Ayyad University- Marrakesh, Morocco.
H. Boumaazi Laboratory of hematology, Military Hospital Avicenne, FMPM- Cadi Ayyad University- Marrakesh, Morocco.
S. Ed-dyb Laboratory of hematology, Military Hospital Avicenne, FMPM- Cadi Ayyad University- Marrakesh, Morocco.
H. Yahyaoui Laboratory of hematology, Military Hospital Avicenne, FMPM- Cadi Ayyad University- Marrakesh, Morocco.
M. Aitameur Laboratory of hematology, Military Hospital Avicenne, FMPM- Cadi Ayyad University- Marrakesh, Morocco.
M. Chakour Laboratory of hematology, Military Hospital Avicenne, FMPM- Cadi Ayyad University- Marrakesh, Morocco.

DOI:

https://doi.org/10.30574/gscarr.2021.7.2.0096

Keywords:

Systemic mastocysis, WHO, Myeloid neoplasms, Acute leukemias, C-Kit mutation

Abstract

Mastocytosis is a heterogeneous group of rare diseases related to the clonal, neoplastic proliferation of morphologically and immunophenotypically abnormal mast cells, that accumulate in one or more organ systems. Their pathophysiology is dominated by activating mutations in C-Kit (Stem Cell Factor receptor). Several pathological forms have been described ranging from isolated cutaneous mastocytosis affecting mainly children, to aggressive systemic mastocytosis described mainly in adults with bone marrow involvement. According to the WHO 2016 classification of hematological malignancies, systemic mastocytosis appear as a new entity of "myeloid neoplasms and acute leukemias" that combines cytology (abnormal mast cells) with other genetic and molecular criteria. We describe through this observation the practical side of hematological cytology in the diagnostic orientation of this serious, rare and underestimated pathology.

Metrics

PDF views

28

|

References

Michot M Hiec M, Galicier L, Lambotte O, Michel M, Bloch-Queyratf C, et al. Le syndrome d’activation lymphohistiocytaire de l’adulte. Revue Med Interne. 2013; 3: 85-93.

Karras A, Hermine O. Hemophagocytic syndrome. La revue de médecine interne. 2002 Sep 1;23(9):768-78.

Pardanani A. Systemic mastocytosis in adults; 2013 update on diagnosis, risk stratification and management. Am J Hematol. 2013 Jul; 88(7):612-24.

S.Barete Les mastocytoses Annales de dermatologie et de vénérologie. 2014; 141: 698-714.

Valent P, Akin C, Metcalfe DD. Mastocytosis; 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017; 129:1420–76.

Voehringer D. Protective and pathological roles of mast cells and basophils. Nat Rev Immunol. 2013; 13:362–75.

Schmetzer O, Valentin P, Church MK, Maurer M, Siebenhaar F. Murine and human mast cell progenitors. Eur J Pharmacol. 2017; 778: 2–10.

Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev. 2007; 217: 65–78.

Galli SJ. The mast cell paradox; from homeostasis to anaphylaxis. Am J Pathol. 2016; 186:212–24.

StJohn AL, Abraham SN. Innate immunity and itsregulation by mast cells.J Immunol. 2013; 190: 4458–63.

Mekori Y, Hershko AY, Frossi B, Mion F, Pucillo CE. Integrating innate and adaptive immune cells; mast cells as cossroads between regulatory and effector B and T cells. Eur J Pharmacol. 2017; 778: 84–9.

Daëron M. Innate myeloid cells under the control of adaptive immunity; the example of mast cells and basophils. Curr Opin Immunol. 2016;38: 101–8.

Chantal B. Aspects cytologiques des Mastocytoses Systémiques. Horizons Hémato - Supplément no.1 au Vol. 07, No. 03. septembre 2017, page number 2.